Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 08 September 2016 | By Michael Mezher
The US Food and Drug Administration (FDA) has issued two new International Council for Harmonisation (ICH) guidelines for public consultation: one on multi-regional clinical trials (MRCTs) and one on microsampling in study animals.
Once ICH adopts a guideline, it then goes to ICH's five regulatory members in the US, EU, Canada, Japan and Switzerland for regional or national consultation before it can be implemented as an internationally harmonized document.
In June, ICH adopted its ICH E17 General Principles for Planning and Design of Multi-Regional Clinical Trials, which is intended to help sponsors design multi-regional clinical trials while reducing unnecessary duplication.
"Globalisation of drug development has increased the use of [multi-regional clinical trials] MRCTs for regulatory submissions in ICH regions as well as in non-ICH regions. Currently, it may be challenging both operationally and scientifically to conduct a drug development programme globally, in part due to distinct and sometimes conflicting requirements from regulatory authorities," the guidance says.
According to the guidance, MRCTs are helpful for drugmakers looking to more quickly recruit trial participants from a more diverse population.
Furthermore, the guidance says that "MRCTs can facilitate simultaneous global drug development by reducing the number of clinical trials that need to be conducted separately in each region, thereby avoiding the ethical issue of unnecessary duplication of studies."
This, the guidance says, can lead to fewer delays in product approval across multiple regions, as the sponsor should be able to submit data from the MRCT to multiple regulators at the same time.
The other draft guidance released is intended to provide clarification on the use of microsampling, which involves drawing tiny amounts of blood—less than 50 microliters (μl)—from animals for testing purposes.
Adopted by ICH in May, ICH S3A Guideline: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure Toxicity Studies, Questions and Answers, provides insights on when pharmaceuticals microsampling is appropriate, sampling methods and the effect they might have on toxicity data, as well as considerations for bioanalytical methods development and validation.
While ICH's primary S3A guideline was implemented in 1994, recent technological advances have allowed for increased use of microsampling in toxicokinetics.
By reducing the amount of blood drawn, ICH says microsampling can reduce pain and distress in study animals, and can even reduce the number of animals required in a toxicokinetics study.
E17 General Principles for Planning and Design of Multi-Regional Clinical Trials
ICH S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies – Questions and Answers
Tags: Multi-regional clinical trials, Microsampling, ICH
Regulatory Focus newsletters
All the biggest regulatory news and happenings.